Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question

Author:

Trouillas Jacqueline1,Burman Pia2ORCID,Losa Marco3ORCID,McCormack Ann4ORCID,Petersenn Stephan5,Popovic Vera6,Theodoropoulou Marily7,Dekkers Olaf M8,Raverot Gerald19ORCID

Affiliation:

1. Faculty of medicine Lyon-Est, University Claude Bernard Lyon 1 , Lyon 69372 , France

2. Department of Endocrinology, Skåne University Hospital, Malmö, Lund University , Malmö 214 28 , Sweden

3. Department of Neurosurgery, IRCCS San Raffaele, Vita-Salute University , Milan 20132 , Italy

4. Department of Endocrinology, St. Vincent's Hospital , Sydney 2010 , Australia

5. ENDOC Center for Endocrine Tumors , Erik-Blumenfeld-Platz 27a, Hamburg 22587 , Germany

6. School of Medicine, University of Belgrade , Belgrade 11000 , Serbia

7. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München , Munich 2333 , Germany

8. Department of Clinical Epidemiology, Leids Universitair Medisch Centrum Centrum voor Humane en Klinische Genetica , Leiden 2300 RC , Netherlands

9. Federation d'Endocrinologie, Hospices civils de Lyon , Bron 69677 , France

Abstract

Abstract From a cohort of 171 patients comprising 121 aggressive pituitary tumours (APT) and 50 pituitary carcinomas (PC), the clinicopathological or five-tiered classification based on tumour invasion and proliferation evaluated by at least 2 proliferative markers over the cut-offs (Ki-67 ≥3% or ≥10%, p53 positive or expressed in %, mitotic count >2%), could be applied on 43 tumours: 20 PC and 23 APT. At the initial surgery, 29/43 tumours (67.4%) were grade 2b (invasive and proliferative) of which 44.8% developed metastases during follow-up (PC, grade 3). Out of these 29 tumours, 55.1% had a Ki-67 ≥10%, and were classified grade 2b* (invasive and highly proliferative). There was one tumour grade 1b* (non-invasive and highly proliferative) which metastazed. Out of the 43 tumours, 30.2 % were grade 2a (invasive and non-proliferative). The sensitivity and the specificity of grade 2b for the diagnosis of APT at the initial surgery, were 68% and 90% respectively. The comparison of the high percentage (67.4%) of grade 2b tumours in this selected cohort of APT/PC with the low percentage (8.8%) in a surgical cohort of unselected tumours shows that the initial pathological diagnosis of grade 2b tumour may be considered, in the clinic, as representing a diagnosis of APT. In addition, a significant subgroup of tumours, which will develop metastases supports the proposal that an aggressive grade 2b tumour is “a tumour with malignant potential” or “a malignant tumour without metastases”. So, the clinician may take into account the pathological diagnosis, at the initial surgery, to propose a strict follow-up and to consider earlier use of radiotherapy and/or of temozolomide in the presence of tumours with aggressive behaviour.

Funder

Ipsen

Rare Diseases/Endocrinology

Publisher

Oxford University Press (OUP)

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3